Anderson MA et al. Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. Blood 2017;129(25):3362-70. Abstract

Byrd JC et al. Acalabrutinib monotherapy in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia: Updated results from the Phase 1/2 ACE-CL-001 study. Proc ASH 2017;Abstract 498.

Davids MS et al. A multicenter, Phase II study of ibrutinib plus FCR (iFCR) as frontline therapy for younger CLL patients. Proc ASH 2017;Abstract 496.

Davids MS. How should we sequence and combine novel therapies in CLL? Hematology Am Soc Hematol Educ Program 2017;2017(1):346-53. Abstract

Flinn IW et al. Safety, efficacy and minimal residual disease negativity of a combination of venetoclax and obinutuzumab in patients with previously untreated chronic lymphocytic leukemia — Results from a phase 1b study. Proc ASH 2017;Abstract 430.

Goede V et al. Overall survival benefit of obinutuzumab over rituximab when combined with chlorambucil in patients with chronic lymphocytic leukemia and comorbidities: Final survival analysis of the CLL11 study. Proc EHA 2018;Abstract S151.  

Gribben JG. How and when I do allogeneic transplant in CLL. Blood 2018;132(1):31-9. Abstract

Jain N et al. Combined venetoclax and ibrutinib for patients with previously untreated high-risk CLL, and relapsed/refractory CLL: A phase II trial. Proc ASH 2017;Abstract 429.

Jones JA et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: An interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol 2018;19(1):65-75. Abstract

Kreitman RJ et al. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia 2018;32(8):1768-77. Abstract

Maddocks KJ et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol 2015;1(1):80-7. Abstract

Michallet AS et al. High rate of complete response but minimal residual disease still detectable after first-line treatment combining obinutuzumab and ibrutinib in chronic lymphocytic leukemia (CLL): ICLL07 FILO trial. Proc EHA 2018;Abstract S804.

O’Brien S et al. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: A 5-year experience. Blood 2018;131(17):1910-9. Abstract

Robak T et al. Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies. Am J Hematol 2018;93(11):1402-10. Abstract

Rogers KA et al. Initial results of the phase 2 treatment naïve cohort in a phase 1b/2 study of obinutuzumab, ibrutinib, and venetoclax in chronic lymphocytic leukemia. Proc ASH 2017;Abstract 431.

Seymour JF et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 2018;378(12):1107-20. Abstract

Stilgenbauer S et al. Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: Results from the full population of a phase II pivotal trial. J Clin Oncol 2018;36(19):1973-80. Abstract

Thompson PA, Wierda WG. Eliminating minimal residual disease as a therapeutic end point: Working toward cure for patients with CLL. Blood 2016;127(3):279-86. Abstract

Thompson PA et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood 2016;127(3):303-9. Abstract

Troussard X, Cornet E. Hairy cell leukemia 2018: Update on diagnosis, risk-stratification, and treatment. Am J Hematol 2017;92(12):1382-90. Abstract

Turtle CJ et al. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib. J Clin Oncol 2017;35(26):3010-20. Abstract

Wierda WG et al. Phase II CAPTIVATE results of ibrutinib (ibr) plus venetoclax (ven) in first-line chronic lymphocytic leukemia (CLL). Proc ASCO 2018;Abstract 7502.

Wierda W et al. Venetoclax in relapsed/refractory chronic lymphocytic leukemia (CLL) with 17p deletion: Outcome and minimal residual disease (MRD) from the full population of the pivotal M13-982 trial. Proc SOHO 2017;Abstract CII-102.